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1. INTRODUCTION {#jmv26338-sec-0010}
===============

Severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐CoV‐2) is the causative agent for coronavirus disease‐2019 (COVID‐19) that has led to nearly 13 million new cases and more than a half‐million deaths as of 11 July 2020.[^1^](#jmv26338-bib-0001){ref-type="ref"} The case fatality rate is significantly higher in elderly, patients with pre‐existing comorbidities, such as hypertension, diabetes, cardiovascular diseases, chronic respiratory disease, and for cancer.[^2^](#jmv26338-bib-0002){ref-type="ref"}, [^3^](#jmv26338-bib-0003){ref-type="ref"}, [^4^](#jmv26338-bib-0004){ref-type="ref"}, [^5^](#jmv26338-bib-0005){ref-type="ref"} The high rate of transmission, moderate case fatality, novel nature of the virus has made the virus a formidable pathogen and has left a huge burden on the healthcare infrastructure.

Enormous amount of research is ongoing for finding vaccines, therapeutic interventions to prevent, mitigate, treat, and manage the complications of COVID‐19 disease. Randomized clinical trials (RCT) form the backbone of an evidence‐based rationale approach for the management of any disease. SARS‐CoV‐2 pandemic has led to a flurry of clinical trials being performed throughout the world. The interventions being tested are largely based on known antiviral activity against SARS and Middle Eastern respiratory syndrome (MERS), efficacy in the in vitro and in vivo models of SARS‐CoV‐2, potential docking sites on the viral genome based on computational modeling studies, and biological agents to counter the cytokine surge and withspread immune activation.[^6^](#jmv26338-bib-0006){ref-type="ref"}, [^7^](#jmv26338-bib-0007){ref-type="ref"} There has also been a surge in interest in repurposing previously approved Food and Drug Administration drugs such as ivermectin, chlorpromazine, isotretinoin, and nitazoxanide for possible antiviral activity.[^8^](#jmv26338-bib-0008){ref-type="ref"}, [^9^](#jmv26338-bib-0009){ref-type="ref"} The simultaneous initiation of multiple clinical trials has led to the redundancy of study design, lack of novelty, and absence of pragmatic primary endpoints. We undertook this systematic review of ongoing interventional clinical trials to collate the available information on the study design, geographical distribution, endpoints assessed, and various drugs that are being assessed in the fight against SARS‐CoV‐2 infections.

2. METHODS {#jmv26338-sec-0020}
==========

This systematic review has been performed and reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (Supporting Information Data).[^10^](#jmv26338-bib-0010){ref-type="ref"}

2.1. Search strategy {#jmv26338-sec-0030}
--------------------

[ClinicalTrials.gov](http://ClinicalTrials.gov), World Health Organization (WHO) International Clinical Trials Registry Platform and PubMed were assessed up to 11 May 2020 with the search terms coronavirus, SARS‐CoV‐2 by two independent investigators (BPV and VTC). The clinical trials from the initial search of the electronic databases were imported into reference manager software. An independent review of the clinical trials was done. The duplicates were removed and the titles of the clinical trials were evaluated. Trials relevant to the topic of interest were shortlisted. The clinical studies that fulfilled the inclusion criteria were shortlisted for the final systematic review. Reasons for excluding clinical studies were documented.

2.2. Inclusion and exclusion criteria {#jmv26338-sec-0040}
-------------------------------------

### 2.2.1. Study selection {#jmv26338-sec-0050}

The following eligibility criteria were used. *Inclusion criteria*: (a) any intervention‐based RCTs, prospective clinical study on SARS‐CoV‐2; and (b) patients ≥18 years of age. *Exclusion criteria*: (a) autopsy series, preclinical studies; (b) studies reporting diagnostic methods, mathematical modeling, epidemiology, and health services research; (c) studies in pediatric populations; and (d) studies on SARS‐CoV and MERS.

2.3. Data extraction {#jmv26338-sec-0060}
--------------------

The data were extracted by two authors independently using a standardized data extraction form based on the SPRINT checklist. The data were extracted on various domains such as trial number, study title, abstract of the study, interventions assessed, sample size, phase of the study, study sponsor, primary endpoint assessed, and country where the study is being done. Any discrepancies in the extraction of data were resolved by mutual discussion (BPV and VTC).

2.4. Definitions {#jmv26338-sec-0070}
----------------

We stratified studies into intervention‐based studies, observational studies, mathematical modeling studies, studies assessing various diagnostic methods for SARS‐CoV‐2, studies that assess health services research, epidemiological studies, and studies on pediatric population.

3. RESULTS {#jmv26338-sec-0080}
==========

3.1. Study search and study characteristics {#jmv26338-sec-0090}
-------------------------------------------

The search of the clinical trial databases resulted in 3242 ongoing studies of which 913 underwent full review and 829 studies were included in the systematic review (Figure [1](#jmv26338-fig-0001){ref-type="fig"}). Amongst the 829 articles,

![PRISMA flow diagram depicting the search strategy utilized in the systematic review](JMV-9999-na-g001){#jmv26338-fig-0001}

463 assessed various drugs as treatment options against COVID‐19; 72 studies assessed preventive options of which 53 are drug‐based prophylaxis and 19 studies assessed vaccines; herbal medicines are being assessed in 79 studies; convalescent plasma therapy (CPT) is being studied in 56 studies; stem cell‐based interventions in 42 studies; anesthesia‐based interventions in 31 studies; machine‐based interventions in 24 studies; mental health‐based interventions in 18 studies; rehabilitation‐based interventions in 12 studies; and miscellaneous interventions in 32 studies. China accounts for 35% (291) of all ongoing clinical studies followed by USA 23% (188), France 7% (63), Spain 3.3% (28), Canada 2% (20), multicountry studies account only for 1.5% (13), and other countries together account for 28% of the studies (Supporting Information Data). There are only 2.77% of clinical trials that specifically seek to enroll patients with comorbidities like diabetes, hypertension, cardiac disease; 2% of the trials that are being done in the elderly and 0.70% in cancer patients accounting for a total of 5.5% ongoing clinical trials.

3.2. Drug‐based interventions as treatment against COVID disease {#jmv26338-sec-0100}
----------------------------------------------------------------

There are 134 different drug‐based interventions being assessed in 463 clinical trials throughout the world (Table [1](#jmv26338-tbl-0001){ref-type="table"}). Amongst the 463 studies assessing drug‐based treatment options, studies that are funded by federal and academic institutions are 79.6%; pharmaceutical company‐funded studies are 15.11% (70); no funding information has been provided in 5.10% (24) studies. The definitive outcomes like mortality were assessed as primary outcome in 22.8% of the studies only and need for mechanical ventilation in 6.2% of the studies. Rest of the studies had outcomes such as: clinical recovery (15.9%), viral clearance (17.4%), time to recovery (10.1%), oxygen improvement (5.6%), ICU admission (1.9%), labs and imaging (6.4%), adverse effects (5.3%) and symptom reduction (1.5%), no outcome reported (6.2%) which account for 71% of the studies. Amongst the pharmaceutical company‐funded drug‐based studies, only 20% of the studies had mortality as the primary outcome and 7% had need for mechanical ventilation as an outcome.

###### 

Summary of mechanisms of the drugs used in the clinical trials as treatment against severe acute respiratory syndrome coronavirus‐2 infection

  -------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antiviral mechanism of action inhibits TMPRSS2/prevents viral cell entry   Immunosuppressants (cytokine surge prevention)       Antioxidants and dietary supplements
  Camostat mesylate                                                          Corticosteroids                                      Alpha‐lipoic acid; vitamin C
  Nafamostat                                                                 Interleukin‐6 inhibitors                             Vitamin D; zinc
  Inhibits S protein/ACE2 interaction                                        Tocilizumab; sarilumab; Siltuximab                   Eicosapentaenoic acid‐free fatty acid
  (Inhibits membrane fusion of the viral envelope)                           Clazakizumab; CMAB806; Ulinastatin                   Triiodothyronine
  Umifenovir (Arbidol)                                                       Naltrexone                                           Anti‐inflammatory
  Angiotensin 1‐7                                                            Interleukin‐1 antagonist                             Aspirin; naproxen; colchicine
  Angiotensin peptide                                                        Anakinra                                             Ibuprofen; CM4620‐injectable
  Angiotensin receptor blockers‐Losartan                                     Anti‐IL‐1β monoclonal antibody                       Tradipitant (neurokinin‐1 receptor (NK‐1R) antagonist)
  Angiotensin‐converting enzyme inhibitors‐ramipril                          Canakinumab                                          Escin; tetrandrine (calcium channel blocker)
  Recombinant human angiotensin‐converting enzyme 2 (rhACE2)                 Interleukin‐8 antagonist                             Bovactant (surfactant)
  Spironolactone                                                             BMS‐986253                                           Ketamine; fluvoxamine
  Inhibits Abl2 kinase activity (inhibits fusion with cell membrane)         Interleukin‐17 inhibitor                             LY3127804(angiopotein‐2 inhibitor)
  Imatinib                                                                   Ixekizumab                                           Metenkefalin + tridecactide
  Inhibits S protein and CD 147 interaction                                  TNF‐alpha inhibitor                                  Antifibrotic agents
  Meplazumab                                                                 Adalimumab                                           cSVF; defibrotide
  Inhibits viral entry and endocytosis                                       XPro1595                                             Pirfenidone; Nintedanib
  Chloroquine                                                                Janus kinase inhibitors                              Vazegepant (an intranasal, high‐affinity calcitonin gene‐related peptide (CGRP) receptor antagonist
  Hydroxychloroquine                                                         Baricitinib; ruxolitinib; Jakotinib                  Iron chelating agent
  Inhibits 3--chymotrypsin‐like protease                                     TD‐0903                                              Desferal
  Lopinavir; darunavir; Ritonavir; danprevir                                 Interferon‐γ antagonist                              
  ASC09; atovaquone, famotidine                                              Emapalumab                                           Miscellaneous
  Inhibitors of viral polymerase complex                                     C5 complement inhibitor                              FT516
  Inhibits viral RNA‐dependent RNA polymerase                                Eculizumab                                           NK cell immunotherapy engineered to express a high affinity, non‐cleavable version of CD16 (hnCD16) for enhanced antibody‐dependent cellular cytotoxicity (ADCC)
  Remdesivir; favipiravir; ribavirin                                         Ravulizumab                                          Methotrexate‐loaded Nanoparticles
  Triazavirin                                                                IFX‐1                                                Inhibitor of Bruton\'s tyrosine kinase (BTK)
  Cap‐dependent endonuclease activity inhibitor                              Phosphoinositide 3‐kinase inhibitor                  Acalabrutinib
  Baloxavir marboxil                                                         Duvelisib                                            Agonist of peripheral chemoreceptors located on the carotid bodies
  Inhibits viral RNA‐dependent DNA polymerase                                Immunomodulators                                     Almitrine
  Emtricitabine/tenofovir                                                    NK cell stimulant                                    Delta‐opioid receptor antagonist
  Azvudine                                                                   AVM0703                                              *Dalargin*
  Clevudine                                                                  T cell stimulants                                    Human vasoactive intestinal polypeptide (VIP)
  Inhibits viral RNA synthesis (NS5B protein)                                Thymosin                                             Aviptadil
  Sofosbuvir; ledipasvir                                                     Anti‐PD1 inhibitor                                   VEGF inhibitor
  Inhibits viral transcription and translation (inhibits protein NS5A)       Nivolumab; camrelizumab                              Bevacizumab
  Daclatasvir                                                                M1 suppression therapy                               Androgen receptor blockade
  Neuraminidase inhibitor                                                    Progesterone                                         Bicalutamide
  Oseltamivir                                                                Myeloid‐derived suppressor cells (MDSC) inhibition   Macrolide antibiotic
  DAS181                                                                     Avdoralimab (C5a receptors (C5aR) inhibitor)         Carrimycin
  Interferons; interferon‐β; Interferon‐α                                    Anti‐GM‐CSF monoclonal antibody                      Unclear mechanism of action
  Interferon‐λ                                                               TJ003234                                             Intravenous immunoglobulin therapy
  Super‐compound interferon (rSIFN‐co)                                       GM‐CSF                                               Suramin sodium
  Enhance type 1 interferon production                                       Sargramostim                                         Etoposide (HLH treatment)
  TAK‐981                                                                    Gimsilumab                                           T89
  Inhibit nuclear transport of virus                                         mTOR inhibitor                                       Oral LL‐37 antiviral peptide (CAS001)
  Ivermectin                                                                 Sirolimus                                            Thymus regeneration and immune restoration
  Viral helicase inhibition                                                  Ubiquitin ligase inhibition                          Somatropin, metformin, and DHEA
  Bismuth                                                                    Lenalidomide                                         
  Calpain inhibitor                                                          Thalidomide                                          
  BLD‐2660                                                                   Dihydroorotate dehydrogenase inhibitor               
  Inhibit viral Claritin                                                     Leflunomide                                          
  Chlorpromazine                                                             CCR5 receptor entry inhibitor                        
  Papain like protease (PLpro) inhibitors                                    Leronlimab                                           
  Isotretinoin                                                               TLR 2/6/9 agonist                                    
  XPO1 inhibitor                                                             PUL‐042 inhalation                                   
  Selinexor                                                                  Miscellaneous                                        
  Other antiviral mechanisms                                                 CD24Fc                                               
  Nitazoxanide                                                               Polyinosinic‐polycytidylic acid                      
                                                                             Recombinant cytokine gene‐derived protein            
                                                                             Estrogen patch                                       
                                                                             Recombinant human plasma gelsolin (rhu‐pGSN)         
                                                                             Mycobacterium w                                      
  -------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
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The most common drug‐based treatment interventions being tested against COVID‐19 are antimalarial medications with 105 clinical studies. Hydroxychloroquine (HCQ) is the most common drug being tested with 83 ongoing studies of which v alone is being studied in 49 studies and HCQ with azithromycin being studied in 22; chloroquine is being tested in 31 studies. Antiviral medications are being tested in 76 clinical trials of which lopinavir with ritonavir in 28 studies, favipiravir in 13 studies, remdesivir in 8 studies, and interferons in 14 studies; other antivirals in 13 studies. Immunosuppressants are being assessed in 82 studies---interleukin‐6 antagonists in 38 studies of which tocilizumab based are 23 studies, sarilumab in 7 studies; corticosteroids in 15 studies; immunomodulators in 30 studies; anti‐inflammatory agents in 20 studies colchicine in 8 studies; antioxidants and dietary supplements such as vitamin C, D, zinc in 16 studies; antifibrotic agents in 9 studies; other miscellaneous interventions account for the rest of the studies. These studies are most commonly done in China (122) followed by USA (114) and France (47) (Supporting Information Data). The largest ongoing clinical trial is the WHO‐sponsored Solidarity trial which is a multicenter study with a sample size of 100 000 patients to assess remdesivir, chloroquine, or HCQ, lopinavir plus ritonavir, interferon‐beta with control, with a primary endpoint of all‐cause mortality.[^11^](#jmv26338-bib-0011){ref-type="ref"}, [^12^](#jmv26338-bib-0012){ref-type="ref"} NCT04292899 is a multicenter study with a sample size of 6000 that is assessing remdesivir with a primary endpoint of improvement on a seven‐point Ordinal Scale on day 14.[^13^](#jmv26338-bib-0013){ref-type="ref"} NCT04322682 is a Canadian study that is assessing colchicine with a primary endpoint of all‐cause mortality at day 30.[^14^](#jmv26338-bib-0014){ref-type="ref"} Table [2](#jmv26338-tbl-0002){ref-type="table"} provides a summary of phase 3 clinical trials with sample size of more than thousand patients that assess various interventions in COVID‐19 disease.

###### 

Summary of drug‐based treatments in phase 3 clinical trials with sample size of more than thousand patients against severe acute respiratory syndrome coronavirus‐2

  Study identification number       Country                                                   Sample size   Intervention assessed                                                                          Primary endpoint
  --------------------------------- --------------------------------------------------------- ------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  NCT04292899                       Multicenter study; sponsor‐Gilead                         6000          Remdesivir                                                                                     The odds of ratio for improvement on a seven‐point Ordinal scale on day 14
  NCT04292730                       Multicenter study; sponsor‐Gilead                         1600          Remdesivir                                                                                     The odds of ratio for improvement on a seven‐point Ordinal Scale on Day 11
  NCT04315948                       Multicenter study; sponsor‐National Institute of France   3000          Remdesivir; lopinavir/ritonavir; interferon β‐1A; hydroxychloroquine                           Percentage of subjects reporting each severity rating on a seven‐point ordinal scale on day 15
  NCT04324047                       France Sponsor‐ Assistance Publique‐Hôpitaux de Paris     1000          Immune modulator drugs                                                                         Overall survival at day 14 WHO progression scale COVID‐19
  NCT04322682                       Canada Sponsor‐Montreal heart institute                   6000          Colchicine                                                                                     Number of participants who die or require hospitalization due to COVID‐19 infection upto day 30
  ISRCTN83971151 Solidarity trial   Multicenter study Sponsor‐WHO                             100000        Remdesivir, chloroquine or hydroxychloroquine, lopinavir plus ritonavir, and interferon‐beta   All‐cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study
  NCT04328012                       USA Sponsor‐ Bassett Healthcare                           4000          Lopinavir/ritonavir; hydroxychloroquine sulfate; losartan                                      National Institute of Allergy and Infectious Diseases COVID‐19 Ordinal Severity Scale (NCOSS) at 60 d
  NCT04345289                       Denmark Sponsor‐Thomas Benfield                           1500          Convalescent anti‐SARS‐CoV‐2 plasma; sarilumab; baricitinib; hydroxychloroquine                All‐cause mortality or need of invasive mechanical ventilation at day 28
  NCT04358068                       USA Sponsor‐NIH                                           2000          Hydroxychloroquine + azithromycin                                                              Proportion of participants who died from any cause or were hospitalized at day 21
  NCT04356495                       France Sponsor‐ University Hospital, Bordeaux             1057          Hydroxychloroquine; imatinib; favipiravir; telmisartan                                         Proportion of participants with an occurrence of hospitalization or death at day 14
  NCT04358003                       USA sponsor‐Marker Therapeutics AG                        2000          Plasma adsorption cartridge                                                                    All‐cause mortality at day 28
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3.3. Drug being tested as prophylaxis against COVID disease {#jmv26338-sec-0110}
-----------------------------------------------------------

Fifty‐three drug‐based studies are being assessed as prophylaxis in COVID‐19. HCQ is the most commonly assessed prophylaxis drug being studied in 24 clinical studies; chloroquine in two studies; HCQ + azithromycin in one study; chloroquine+ azithromycin in one study; nitazoxanide in two studies; other antiviral medications include Camostat mesylate, interferons, lopinavir + ritonavir. Other immunomodulatory medications being assessed include anakinra, colchicine, corticosteroids, levamisole, Mycobacterium W in one study each. Table [3](#jmv26338-tbl-0003){ref-type="table"} provides a summary of the prophylactic interventions being assessed against COVID‐19. The most common country where these studies are conducted are USA[^17^](#jmv26338-bib-0017){ref-type="ref"} followed by four each in France and China (Supporting Information Data). The largest of the prophylactic study is the Crown coronation study that is a multicenter study with a sample size of 55 000 that is assessing various doses of chloroquine in the effectiveness in preventing laboratory‐confirmed symptomatic COVID‐19 in healthcare workers with repeated exposures to SARS‐CoV‐2.[^15^](#jmv26338-bib-0015){ref-type="ref"} The next largest study is the CRASH 19 study conducted in the UK with a sample size of 10 000 that is assessing aspirin, losartan, and simvastatin with the all‐cause mortality as the primary endpoint.[^16^](#jmv26338-bib-0016){ref-type="ref"} WHIP COVID study is a multicenter study assessing the efficacy of weekly vs daily HCQ in preventing new cases of SARS‐CoV‐2 infection.[^17^](#jmv26338-bib-0017){ref-type="ref"}

###### 

Summary of preventive phase 3 clinical trials with sample size of more than thousand patients against severe acute respiratory syndrome coronavirus‐2 infection

  Study identification number   Country                                                  Sample size   Intervention assessed                                         Primary endpoint
  ----------------------------- -------------------------------------------------------- ------------- ------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  NCT04333407                   United Kingdom                                           3170          Aspirin; clopidogrel; rivaroxaban; atorvastatin; omeprazole   All‐cause mortality at 30 d after admission
  Phase 3 trial                 Sponsor‐Imperial College London                                                                                                      
  NCT04333732                   Multicenter study                                        55 000        Different doses of chloroquine                                Effectiveness in preventing laboratory‐confirmed symptomatic COVID‐19 in healthcare workers with repeated exposures to SARS‐CoV‐2
  Phase 3 trial                 Sponsor‐Bill and Melinda Gates Foundation                                                                                            
  Crown coronation study                                                                                                                                             
  NCT04334967                   USA                                                      1250          Hydroxychloroquine                                            Percentages of enrolled patients needing hospitalization and mechanical ventilation at day 14
  Phase 3 trial                 Sponsor‐ Providence Health & Services                                                                                                
  NCT04328467                   USA                                                      3500          Hydroxychloroquine                                            Outcome reported as the percent of participants in each arm who are COVID‐19‐free at the end of study treatment upto 12 wk
  Phase 3 trial                 Sponsor‐University of Minnesota                                                                                                      
  NCT04341441                   USA                                                      3500          Hydroxychloroquine daily vs weekly dosing                     Measure the difference in new cases of COVID‐19 disease between randomized treatment arms at 8 wk
  Phase 3 trial                 Sponsor‐Henry Ford Health System                                                                                                     
  WHIP COVID study                                                                                                                                                   
  NCT04342156                   Singapore                                                1200          Hydroxychloroquine                                            Positive serology or reverse transcriptase (RT‐PCR) for COVID‐19 up until day 28
  Phase 3 trial                 Sponsor‐Tan Tock Seng Hospital                                                                                                       
  NCT04343001                   United Kingdom                                           10 000        Aspirin, losartan, and simvastatin                            Death upto 28 d from day of randomization
  Phase 3 trial                 Sponsor‐London School of Hygiene and Tropical Medicine                                                                               
  CRASH 19 study                                                                                                                                                     
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3.4. Vaccines {#jmv26338-sec-0120}
-------------

The most important option to prevent further waves of the COVID pandemic is vaccines. There are 19 vaccine‐based studies of which are eight are BCG and one measles vaccine‐based studies; 11 are newer vaccine candidates. The most commonly studied vaccine is the BCG vaccine in eight studies followed by recombinant novel coronavirus vaccine (adenovirus type vector) in two studies, aAPC Vaccine, minigene vaccine, recombinant chimeric COVID‐19 epitope DC vaccine, bacTRL‐Spike vaccine, measles vaccine, mRNA‐1273 vaccine, nanoparticle vaccine, ChAdOx1 nCoV‐19, and INO‐4800. China is leading the initiative with four ongoing human trials followed by the USA with three trials. Supporting Information Data provides a summary of the ongoing vaccine‐based studies around the world.

3.5. Mesenchymal stem cell therapy {#jmv26338-sec-0130}
----------------------------------

There are currently 42 clinical studies that are assessing mesenchymal stem cell therapy‐based interventions in COVID‐19 disease. China is leading the initiative with 25 ongoing human trials followed by the USA with eight trials and Spain with four trials. The rationale for the use of mesenchymal stem cells are the hypothesized immunomodulatory properties that can counter the cytokine storm. The various sources of stem cells that are being studied include cord blood, human menstrual blood‐derived, mesenchymal stem cells exosomes atomization, human dental pulp, human stromal cells, umbilical cord blood mononuclear cells, and umbilical cord Wharton\'s Jelly‐derived mesenchymal stem cells (Table [4](#jmv26338-tbl-0004){ref-type="table"}).

###### 

Summary of interventions used in the clinical trials as prevention against severe acute respiratory syndrome coronavirus‐2 infection

  Prevention                               Vaccines
  ---------------------------------------- ----------------------------------------------------------
  Pre and postexposure prophylaxis         Recombinant novel coronavirus vaccine
  Antiviral medications                    (Adenovirus type 5 vector)
  Hydroxychloroquine                       aAPC vaccine
  Chloroquine                              Minigene vaccine
  Lopinavir/ritonavir                      Recombinant chimeric COVID‐19 epitope DC
  Interferon alpha                         BCG V
  Camostat Mesylate                        bacTRL‐Spike
  Peginterferon λ‐1a                       Measles
  Nitazoxanide                             RNA vaccine candidate
  Anti‐inflammatory                        mRNA‐1273 vaccine
  Anakinra                                 Nanoparticle vaccine
  Colchicine                               Recombinant novel coronavirus (adenovirus type 2 vector)
  Corticosteroids                          ChAdOx1 nCoV‐19
  Immunomodulators                         INO‐4800
  Levamisole and isoprinosine              Nonpharmacological interventions
  Lactobacillus coryniformis K8            App‐based social distancing
  Lenzilumab                               Face masks vs N95 respirator
  Miscellaneous                            Internet‐based solutions
  Vitamin C; vitamin D; zinc               Isolation strategy
  Melatonin                                
  Mycobacterium w                          
  rhIFNa nasal drops                       
  Resistant potato starch                  
  Nitric oxide                             
  Bêta‐cyclodextrin and Citrox mouthwash   
  Povidone‐iodine 0.5% nasal               
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3.6. Convalescent plasma therapy {#jmv26338-sec-0140}
--------------------------------

CPT involves infusion of plasma obtained from people who have recovered from COVID‐19 and who have circulating neutralizing antibodies that provide short‐term immunity against SARS‐CoV‐2 coronavirus. There are currently 56 ongoing studies that are assessing CPT with 20 studies being done in the USA and 14 studies being done in China. The largest ongoing clinical trial is the CONCOR‐1 study being done in Canada with a sample size of 1000 patients with the aim to assess if CPT reduces in‐hospital mortality in patients hospitalized for COVID‐19 (Table [4](#jmv26338-tbl-0004){ref-type="table"}).

3.7. Herbal medicines {#jmv26338-sec-0150}
---------------------

There are currently 79 clinical studies assessing the efficacy of alternative medicines mainly the Chinese herbals that are being assessed in 77 studies followed by one study in Iran and one Ayurveda study in UK Table [5](#jmv26338-tbl-0005){ref-type="table"}.

###### 

Summary of nonpharmacological interventions used in the clinical trials as treatment against severe acute respiratory syndrome coronavirus‐2 infection

  -----------------------------------------------------------------
  Cell and plasma‐based therapy
  Convalescent plasma therapy
  Cell‐based therapy
  Cord blood mesenchymal stem cells
  Human menstrual blood‐derived stem cells mesenchymal stem cells
  Mesenchymal stem cells exosomes atomization
  Human dental pulp mesenchymal stem cells
  Human stromal cells
  Umbilical cord blood mononuclear cells
  Umbilical cord Wharton\'s Jelly‐derived mesenchymal stem cells
  Machine‐based interventions
  Extracorporeal membrane oxygenation
  CytoSorb absorber
  External diaphragmatic pacing
  Hyperbaric oxygen therapy
  Bidirectional oxygen valve
  oXiris membrane
  Plasmapheresis
  V/Q vest
  Dialysis
  Anesthesia‐based interventions
  Nitric oxide
  Prone positioning
  Noninvasive oscillating device (NIOD)
  Sedation with sevoflurane vs propofol
  Double‐trunk mask on oxygenation titration
  Early CPAP
  Intubation barrier box
  Miscellaneous
  Chinese herbal medicines
  Mental health and mindfulness interventions
  Telerehabilitation
  Acupressure therapy
  Respiratory muscle training
  Auricular nerve stimulation
  Expressive writing
  Hydrogen inhalation
  Ozone autohemotherapy
  Prayer
  shadowboxing for pulmonary function
  Sleep psychology and music therapy
  Neck inspiratory muscle exercise
  Radiation therapy
  Zang‐Fu Point‐pressing\' massage
  Virtual monitoring
  -----------------------------------------------------------------
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Supporting Information Data provides a summary of the various ongoing studies that are testing herbal medicines against COVID‐19.

3.8. Anesthesia‐based interventions {#jmv26338-sec-0160}
-----------------------------------

There are currently 31 ongoing studies that assess various anesthesia‐based interventions that include prone positioning,[^11^](#jmv26338-bib-0011){ref-type="ref"} nitric oxide inhalation,[^7^](#jmv26338-bib-0007){ref-type="ref"} ventilator settings,[^8^](#jmv26338-bib-0008){ref-type="ref"} and modified intubation techniques.[^5^](#jmv26338-bib-0005){ref-type="ref"} USA is performing seven studies followed by Canada with five studies.

3.9. Machine‐based interventions {#jmv26338-sec-0170}
--------------------------------

There are currently 24 ongoing studies that are assessing machine‐based interventions such as extracorporeal membrane oxygenation (8), plasmapheresis (5), CytoSorb adsorber (3), Bidirectional Oxygenation Valve (2), hyperbaric oxygen therapy (2), continuous renal replacement therapy (2), external diaphragmatic pacing (1), oXiris membrane (1), and V/Q Vest(1).

3.10. Mental health {#jmv26338-sec-0180}
-------------------

There is excess emotional distress to patients and healthcare providers during the COVID‐19 pandemic. There are 18 studies that are assessing mental health‐based interventions that include mindfulness (11) meditation (3), intelligent psychosomatic adjustment system (2), cognitive behavioral therapy (1), and psychological support. China is performing eight studies followed by the USA with four studies.

3.11. Rehabilitation {#jmv26338-sec-0190}
--------------------

There are currently 12 studies that are assessing various rehabilitation initiatives such as telerehabilitation‐based exercises (6), general rehabilitation (2), pulmonary rehabilitation (2) anosmia rehabilitation (1), and rehab‐meals (1). China and Turkey are leading with three studies each.

3.12. Others {#jmv26338-sec-0200}
------------

There are 32 other intervention‐based studies that were not categorized into the above distinctions. They include microbiota transplantation (3), natural killer cell (CYNK‐001) infusions (3), acupressure therapy at auricular point (3), hydrogen inhalation (3), radiation therapy (2), respiratory muscle training (2), digital stress through artificial intelligence(2), ozone autohemotherapy (2), virtual monitoring (2), expressive writing (1), face mask (1), Internet‐based solution (1), medical masks vs N95 respirators (1), online distance learning (1), prayer (1), shadowboxing for pulmonary function (1), sleep psychology and music therapy (1), Zang‐Fu Point‐pressing massage (1), and endo‐venous systemic Ozone therapy(1).

4. DISCUSSION {#jmv26338-sec-0210}
=============

In this systematic review, we critically appraise 829 ongoing clinical trials that are assessing various interventions such as treatment, drug‐based prophylaxis, herbal medicines, CPT, stem cell‐based interventions, anesthesia‐based interventions, machine‐based interventions, mental health‐based interventions, rehabilitation‐based interventions, and miscellaneous interventions. China and USA account for the majority of the ongoing studies with concern that patients in middle‐ and low‐income countries may have minimal access for enrollment into clinical trials. Multicenter multicountry collaborative studies account only for 1.5% of all ongoing clinical studies, which show apparent lack of collaborative effort among researchers as well as difficult in universal applicability of the conclusions made from ongoing studies done in developed countries.

The major overwhelming nature of this pandemic has been case fatality rates of 1%‐10% seen in different healthcare settings and the high demand for ventilatory support. Despite this, 71% of the clinical trials have surrogate endpoints other than all‐cause mortality or ventilatory support as the primary endpoint. In addition, the case fatality rate is significantly higher in elderly, patients with pre‐existing comorbidities such as hypertension, diabetes, cardiovascular diseases, chronic respiratory disease, and cancer. Despite this, only 5.5% of the ongoing clinical trials specifically seek to enroll this subgroup of patients. This causes significant concern regarding applicability of the ongoing clinical trials to the general population and the degree of applicability of the clinical trial data to patients with comorbidities.[^18^](#jmv26338-bib-0018){ref-type="ref"}, [^19^](#jmv26338-bib-0019){ref-type="ref"}

The most common interventions are drug‐based directed at treatment of COVID‐19 disease in 463 clinical trials. Though the main pathophysiology behind mortality, intubation, ICU admissions are cytokine storm and macrophage activation, nearly 50% of studies are antiviral activity‐based interventions with antimalarial accounting for 105 studies and other antiviral drugs accounting for 76 studies.[^20^](#jmv26338-bib-0020){ref-type="ref"} The main clinical rationale for use of antimalarial agent against SARS‐CoV‐2 was based on in vitro efficacy. Despite lack of mortality benefit and possible increased risk of adverse events with HCQ in published clinical studies till date, it is still the most commonly studied drug against SARS‐CoV‐2.[^21^](#jmv26338-bib-0021){ref-type="ref"}, [^22^](#jmv26338-bib-0022){ref-type="ref"} This calls for a need for an international repository of individual patient data and rapid assimilation of the available clinical evidence on deciding termination of potentially harmful interventions.[^23^](#jmv26338-bib-0023){ref-type="ref"} Biological agents with immunosuppressive and immunomodulatory properties that have the potential to curb the cytokine storm and withspread macrophage activation are being studied with close to 100 studies ongoing.[^12^](#jmv26338-bib-0012){ref-type="ref"}

The most important area for research in the current pandemic needs to be preventive studies. There are currently 72 studies with 19 vaccine‐based and 53 drug‐based preventive studies. There are currently 11 vaccines in human clinical trials. BCG vaccine is also being also studied for its proposed immunogenicity against SARS‐CoV‐2.[^24^](#jmv26338-bib-0024){ref-type="ref"} Among the drug‐based preventive studies, 50% are using HCQ with various aspects being tested including daily vs weekly dosing, pre‐ vs postexposure prophylaxis. From our review, we feel there is a greater need for more preventive strategy‐based studies since most of the countries are reopening and the proposed timeline for the pandemic to subside is 1 to 2 years.[^25^](#jmv26338-bib-0025){ref-type="ref"} CPT use in COVID‐19 disease was promoted by the potential efficacy in SARS, MERS, and Ebola.[^26^](#jmv26338-bib-0026){ref-type="ref"} There are currently 56 studies that are ongoing and from some of the published data, it has been shown to be safe and effective. There is a need for information from larger datasets.

There are 79 studies that are assessing herbal‐based medicines and 42 studies that are assessing mesenchymal stem cells therapy. Majority of these studies are being done in China (%). These interventions are questionable with a potential to harm patients. There is a trend to combine these interventions with western medicines and the potential drug interactions may lead to further adverse events. One of the important aspects that this systematic review shows is the lack of enough studies on rehabilitation and mental health‐related interventions. There are only 30 studies that account only for 3% of all intervention‐based studies that are ongoing. Home quarantine, emotional distress from loss of loved ones, loss of job, new oxygen requirements from COVID disease, anosmia are some of the problems faced by patients recovering from COVID‐19. There is a huge need for more studies that focus on alleviating these problems. Majority of the patients with severe or critical COVID disease are in ICU. There are only 31 ongoing studies that are ICU‐based interventions like prone positioning, nitric oxide inhalation. There is a greater need for study of potential interventions that can improve outcomes in patients admitted in the ICU.

4.1. Strengths of the systematic review {#jmv26338-sec-0220}
---------------------------------------

This is an extensive review of the ongoing clinical studies to give an insight into the various interventions being studied currently. We were also able to identify the outcomes being studied and provide inputs on the need for studies addressing definitive patient‐related outcomes like mortality, and need for mechanical ventilation and improvement of patients in the ICU. Our review also provides information regarding the utility of ongoing trials like HCQ‐based treatment, which have so far not shown benefit in larger studies, and reassess the need for such studies and utilize resources for other interventions.

4.2. Limitations {#jmv26338-sec-0230}
----------------

Newer clinicals are being rapidly initiated and enrolled into the clinical trial registries which makes it difficult for the review to be up to date. Information regarding the status of clinical trials if they are active or have been terminated or completed is not clearly available from the databases. Though the review accounted for most of the clinical trial registries, despite our best attempt, it may not be exhaustive enough to account for retrospective registration of all studies.

4.3. Implications for practice {#jmv26338-sec-0240}
------------------------------

The majority of ongoing clinical trials seek to enroll patients that may not be representative of the actual population who are at risk of death and morbidity from COVID‐19. There needs to be an emphasis on the rationality of the primary endpoints with need for all‐cause mortality as the primary endpoint and other patient‐related outcomes like need for mechanical ventilation and decreasing length of ICU stay as main secondary outcomes. There needs to be a higher rate of inclusion of patients with comorbidities in clinical trials to reflect real‐world scenario for outcomes. Majority of ingoing studies are in the developed world and middle‐ and low‐income countries are at a risk of grossly being underrepresented in the clinical trials.

5. CONCLUSION {#jmv26338-sec-0250}
=============

This systematic review identifies the spectrum of clinical trials and the therapeutic interventions that are being assessed against SARS‐CoV‐2. Multiple intervention‐based clinical studies against SARS‐CoV‐2 are being done throughout the world with a high concentration of clinical trials being done in the developed world. There is a high concern for redundancy of studies and underrepresentation of elderly and patients with comorbidities. Definite endpoints like mortality are being assessed in only one‐fifth of the studies. This review provides information for researchers for the rationale design of future clinical studies.
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